← All trials
NCT05682352
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 7, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Jan 12, 2023
- Last posted
- Aug 28, 2023
- Enrollment
- 104
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leo PharmaLead sponsor
- Leo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.